Main Differences Highlighted The debate saw Romana Jerković (S&D) and Viktória Ferenc (PfE) sharply divided on the scope of EU cardiovascular prevention policies, especially regarding the inclusion of commercial determinants of health and taxation powers. Jerković advocated for a broad prevention approach targeting structural factors like alcohol and tobacco, supported by EU-level tax and labelling regulations. Ferenc urged restraint, emphasizing that healthcare and taxation remain primarily national competences, favoring a narrower scope focused on compromise. Meanwhile, on public health funding, Radan Kanév (EPP) and Vlad Vasile-Voiculescu (Renew) clashed over the role and design of funding instruments, with Kanév supporting a dedicated health funding window within the European Competitiveness Fund, while Vasile-Voiculescu tied health funding more explicitly to sovereignty, biodefense, and military readiness.
Context of the Debate These differences unfolded during the European Parliament's Committee on Public Health meeting (SANT) held on 18 March 2026, which tackled the EU cardiovascular diseases strategy, the European Competitiveness Fund, the Critical Medicines Act, and rare diseases policy.
Concrete Proposals Versus General Assurances Jerković’s report was anchored by extensive amendments (over 1,000) emphasizing prevention, equity, and evidence-based policies including digital tools and monitoring inequalities. She pushed for EU-level policies addressing commercial determinants like alcohol and tobacco, with taxation mentioned as a mechanism to promote healthier choices. Vasile-Voiculescu proposed a €10 billion ring-fenced health funding window linked explicitly to sovereignty, biodefense, antimicrobial resistance (AMR), and climate-health intersections. Kanév defended earmarked funding for health but remained cautious on integrating health with defense or competitiveness priorities.
Ferenc, while supportive of healthy living and screening, refrained from endorsing EU-level taxation or broad public health mandates, urging respect for national sovereignty and committee limits. Margarita de la Pisa Carrión (PfE) echoed concerns that the Competitiveness Fund overemphasized climate, security, and defense at the expense of health’s strategic potential.
Policy Orientations and Cleavages A clear cleavage emerged on increasing versus restraining EU competences: Jerković and allies leaned toward expanding EU regulatory and fiscal powers over commercial health determinants, envisaging health as a cross-sectoral priority including taxation and environmental policies. Conversely, Ferenc and certain EPP members advocated preserving national sovereignty over taxation and healthcare, favoring subsidiarity. On funding, Kanév supported a health-dedicated budget window within the broader Competitiveness Fund, emphasizing treatment and prevention, while Vasile-Voiculescu pushed a broader strategic link to EU sovereignty and defense. This presents a dichotomy between viewing health policy as a social welfare priority versus linking it to industrial and security frameworks.
Stakeholder Impact For EU producers and pharmaceutical industry sectors, the Critical Medicines Act and related provisions promise regulatory clarity, faster procedures, and incentives for rare and orphan medicines, with positive implications for innovation but also potentially increased compliance costs. EU consumers and patients, particularly in cardiovascular and rare disease domains, stand to benefit from stronger prevention, earlier diagnosis, and better access to treatment, although stakeholders in member states valuing national sovereignty might see EU regulatory ambitions as intrusive. National authorities face balancing acts in adopting EU recommendations on health checks and prevention while respecting domestic competences.
Follow-up Expectations The debate concluded with the committee approving all pilot projects and pharma package agreements, pointing towards gradual legislative finalization. The next steps include SANT voting on 14 April and deadlines for further opinions by 24 April. Given the expressed divergences, subsequent negotiations will likely focus on calibrating EU versus national powers, funding architecture, and the health-security nexus in upcoming legislation and funding programs.